INCRUSE ELLIPTA
LAMA DPI
Umeclidinium bromide · GlaxoSmithKline
Active Medication & Mechanism
- Umeclidinium bromide LAMA62.5 mcg per blister
Long-acting muscarinic antagonist (anticholinergic). Competitively and reversibly inhibits M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 62.5 mcg | Adults (≥18 years) | 1 inhalation once daily Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD. | 62.5 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Incruse Ellipta is NOT indicated for asthma. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |